

Organ Transplant Immunosuppressant Drugs Market Size, Share & Trends Analysis Report By Drug Class (Calcineurin Inhibitors, Antiproliferative Agents), By Transplant Type, By Region, And Segment Forecasts, 2025 - 2030

<https://marketpublishers.com/r/OE7131E23CB1EN.html>

Date: November 2024

Pages: 110

Price: US\$ 5,950.00 (Single User License)

ID: OE7131E23CB1EN

Abstracts

This report can be delivered to the clients within 3 Business Days

Organ Transplant Immunosuppressant Drugs Market Growth & Trends

The global organ transplant immunosuppressant drugs market size is estimated to reach USD 7.24 billion by 2030, registering a CAGR of 4.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing patient population requiring organ transplantations and increasing approval of novel products are the factors driving the market growth. However, the high procedural cost of transplantations, the disproportion in the supply and demand for organs, and uncertain reimbursement scenarios are the major factors restraining the market growth.

According to the Health Resources & Services Administration and the U.S. Department of Health and Human Services, more than 113,000 people were in need of transplants as of January 2019 and 36,528 transplants were performed in 2018. Hence, there is huge demand for organ transplants that will further boost the market. Kidney transplant held the largest market share in the transplant segment and is expected to retain its leading position through the forecast period. This can be attributed to increasing demand and comparatively better availability of kidneys than other organs.

Among the drug classes, the calcineurin inhibitors are expected to dominate the global organ transplant immunosuppressant drugs market through the forecast period. There

are two drugs in this drug class, Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). Although these effective immunosuppressants have been used in kidney transplant recipients for more than 20 years, they hold extensive toxicity profiles. Asia Pacific is expected to show the highest CAGR, while North America is expected to hold the largest share during the forecast period.

Organ Transplant Immunosuppressant Drugs Market Report Highlights

Calcineurin inhibitors are expected to command the largest market share in the drug class segment. Calcineurin inhibitors inhibit the activation action of T-cells of the immune system by the enzyme calcineurin.

Calcineurin inhibitors such as tacrolimus and cyclosporine are the cornerstone of immunosuppression for kidney transplantation. In more than 85% cases of kidney transplant, tacrolimus is prescribed as a part of the patients' maintenance immunosuppressive regimen.

Based on transplant type, the kidney transplant held the largest market share of 49.1% in 2024, due to the increasing demand for kidney replacement procedures.

Asia Pacific regional market is expected to demonstrate the fastest growth over the forecast period due to rising per capita healthcare expenditure, improving healthcare infrastructure, and increasing demand for organ transplantations in the region.

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Drug Class
 - 1.2.2. Transplant Type
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
 - 1.5.1. Purchased Database
 - 1.5.2. GVR's Internal Database
 - 1.5.3. Secondary Sources
 - 1.5.4. Primary Research
- 1.6. Information Analysis
 - 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
 - 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot

CHAPTER 3. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
 - 3.2.1. Market Driver Analysis
 - 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
 - 3.3.1. Industry Analysis - Porter's Five Forces Analysis
 - 3.3.1.1. Supplier Power

- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis

CHAPTER 4. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: DRUG CLASS BUSINESS ANALYSIS

- 4.1. Drug Class Market Share, 2024 & 2030
- 4.2. Drug Class Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
- 4.4. Calcineurin Inhibitors
 - 4.4.1. Calcineurin Inhibitors Market, 2018 - 2030 (USD Million)
- 4.5. Antiproliferative Agents
 - 4.5.1. Antiproliferative Agents Market, 2018 - 2030 (USD Million)
- 4.6. mTOR Inhibitor
 - 4.6.1. mTOR Inhibitor Market, 2018 - 2030 (USD Million)
- 4.7. Steroids
 - 4.7.1. Steroids Market, 2018 - 2030 (USD Million)
- 4.8. Other Drug Classes
 - 4.8.1. Other Drug Classes Market, 2018 - 2030 (USD Million)

CHAPTER 5. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: TRANSPLANT TYPE BUSINESS ANALYSIS

- 5.1. Transplant Type Market Share, 2024 & 2030
- 5.2. Transplant Type Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Transplant Type, 2018 to 2030 (USD Million)
- 5.4. Kidney
 - 5.4.1. Kidney Market, 2018 - 2030 (USD Million)
- 5.5. Liver
 - 5.5.1. Liver Market, 2018 - 2030 (USD Million)
- 5.6. Heart
 - 5.6.1. Heart Market, 2018 - 2030 (USD Million)
- 5.7. Lung
 - 5.7.1. Lung Market, 2018 - 2030 (USD Million)

5.8. Pancreas

5.8.1. Pancreas Market, 2018 - 2030 (USD Million)

5.9. Other Transplant Types

5.9.1. Other Transplant Types Market, 2018 - 2030 (USD Million)

CHAPTER 6. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG CLASS AND TRANSPLANT TYPE

6.1. Regional Market Share Analysis, 2024 & 2030

6.2. Regional Market Dashboard

6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:

6.4. North America

6.4.1. North America Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.4.2. U.S.

6.4.2.1. Key Country Dynamics

6.4.2.2. Regulatory Framework

6.4.2.3. Competitive Insights

6.4.2.4. U.S. Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.4.3. Canada

6.4.3.1. Key Country Dynamics

6.4.3.2. Regulatory Framework

6.4.3.3. Competitive Insights

6.4.3.4. Canada Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.4.4. Mexico

6.4.4.1. Key Country Dynamics

6.4.4.2. Regulatory Framework

6.4.4.3. Competitive Insights

6.4.4.4. Mexico Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5. Europe

6.5.1. Europe Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.5.2. UK

6.5.2.1. Key Country Dynamics

6.5.2.2. Regulatory Framework

6.5.2.3. Competitive Insights

6.5.2.4. UK Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5.3. Germany

6.5.3.1. Key Country Dynamics

6.5.3.2. Regulatory Framework

6.5.3.3. Competitive Insights

6.5.3.4. Germany Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5.4. France

6.5.4.1. Key Country Dynamics

6.5.4.2. Regulatory Framework

6.5.4.3. Competitive Insights

6.5.4.4. France Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5.5. Italy

6.5.5.1. Key Country Dynamics

6.5.5.2. Regulatory Framework

6.5.5.3. Competitive Insights

6.5.5.4. Italy Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5.6. Spain

6.5.6.1. Key Country Dynamics

6.5.6.2. Regulatory Framework

6.5.6.3. Competitive Insights

6.5.6.4. Spain Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5.7. Norway

6.5.7.1. Key Country Dynamics

6.5.7.2. Regulatory Framework

6.5.7.3. Competitive Insights

6.5.7.4. Norway Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5.8. Denmark

6.5.8.1. Key Country Dynamics

6.5.8.2. Regulatory Framework

6.5.8.3. Competitive Insights

6.5.8.4. Denmark Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5.9. Sweden

6.5.9.1. Key Country Dynamics

6.5.9.2. Regulatory Framework

6.5.9.3. Competitive Insights

6.5.9.4. Sweden Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.6. Asia Pacific

6.6.1. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.2. Japan

6.6.2.1. Key Country Dynamics

6.6.2.2. Regulatory Framework

6.6.2.3. Competitive Insights

6.6.2.4. Japan Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.3. China

6.6.3.1. Key Country Dynamics

6.6.3.2. Regulatory Framework

6.6.3.3. Competitive Insights

6.6.3.4. China Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.4. India

6.6.4.1. Key Country Dynamics

6.6.4.2. Regulatory Framework

6.6.4.3. Competitive Insights

6.6.4.4. India Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.5. Australia

6.6.5.1. Key Country Dynamics

6.6.5.2. Regulatory Framework

6.6.5.3. Competitive Insights

6.6.5.4. Australia Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.6. South Korea

6.6.6.1. Key Country Dynamics

6.6.6.2. Regulatory Framework

6.6.6.3. Competitive Insights

6.6.6.4. South Korea Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.7. Thailand

6.6.7.1. Key Country Dynamics

6.6.7.2. Regulatory Framework

6.6.7.3. Competitive Insights

6.6.7.4. Thailand Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.7. Latin America

6.7.1. Latin America Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.7.2. Brazil

6.7.2.1. Key Country Dynamics

6.7.2.2. Regulatory Framework

6.7.2.3. Competitive Insights

6.7.2.4. Brazil Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.7.3. Argentina

6.7.3.1. Key Country Dynamics

6.7.3.2. Regulatory Framework

6.7.3.3. Competitive Insights

6.7.3.4. Argentina Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.8. MEA

6.8.1. MEA Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.8.2. South Africa

6.8.2.1. Key Country Dynamics

6.8.2.2. Regulatory Framework

6.8.2.3. Competitive Insights

6.8.2.4. South Africa Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.8.3. Saudi Arabia

6.8.3.1. Key Country Dynamics

6.8.3.2. Regulatory Framework

6.8.3.3. Competitive Insights

6.8.3.4. Saudi Arabia Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.8.4. UAE

6.8.4.1. Key Country Dynamics

6.8.4.2. Regulatory Framework

- 6.8.4.3. Competitive Insights
- 6.8.4.4. UAE Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.8.5. Kuwait
 - 6.8.5.1. Key Country Dynamics
 - 6.8.5.2. Regulatory Framework
 - 6.8.5.3. Competitive Insights
 - 6.8.5.4. Kuwait Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

CHAPTER 7. COMPETITIVE LANDSCAPE

- 7.1. Participant Overview
- 7.2. Company Market Position Analysis
- 7.3. Company Categorization
- 7.4. Strategy Mapping
- 7.5. Company Profiles/Listing
 - 7.5.1. Astellas Pharma d.o.o.
 - 7.5.1.1. Overview
 - 7.5.1.2. Financial Performance
 - 7.5.1.3. Product Benchmarking
 - 7.5.1.4. Strategic Initiatives
 - 7.5.2. Sanofi
 - 7.5.2.1. Overview
 - 7.5.2.2. Financial Performance
 - 7.5.2.3. Product Benchmarking
 - 7.5.2.4. Strategic Initiatives
 - 7.5.3. Accord Healthcare
 - 7.5.3.1. Overview
 - 7.5.3.2. Financial Performance
 - 7.5.3.3. Product Benchmarking
 - 7.5.3.4. Strategic Initiatives
 - 7.5.4. Novartis AG
 - 7.5.4.1. Overview
 - 7.5.4.2. Financial Performance
 - 7.5.4.3. Product Benchmarking
 - 7.5.4.4. Strategic Initiatives
 - 7.5.5. Viatris Inc.
 - 7.5.5.1. Overview

- 7.5.5.2. Financial Performance
- 7.5.5.3. Product Benchmarking
- 7.5.5.4. Strategic Initiatives
- 7.5.6. F. Hoffmann-La Roche Ltd
 - 7.5.6.1. Overview
 - 7.5.6.2. Financial Performance
 - 7.5.6.3. Product Benchmarking
 - 7.5.6.4. Strategic Initiatives
- 7.5.7. GlaxoSmithKline plc.
 - 7.5.7.1. Overview
 - 7.5.7.2. Financial Performance
 - 7.5.7.3. Product Benchmarking
 - 7.5.7.4. Strategic Initiatives
- 7.5.8. Veloxis Pharmaceuticals, Inc.
 - 7.5.8.1. Overview
 - 7.5.8.2. Financial Performance
 - 7.5.8.3. Product Benchmarking
 - 7.5.8.4. Strategic Initiatives
- 7.5.9. Bristol-Myers Squibb Company
 - 7.5.9.1. Overview
 - 7.5.9.2. Financial Performance
 - 7.5.9.3. Product Benchmarking
 - 7.5.9.4. Strategic Initiatives

I would like to order

Product name: Organ Transplant Immunosuppressant Drugs Market Size, Share & Trends Analysis Report By Drug Class (Calcineurin Inhibitors, Antiproliferative Agents), By Transplant Type, By Region, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/OE7131E23CB1EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OE7131E23CB1EN.html>